TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28390695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril and telmisartan (n=8334)
Study: 28390695
Drug: Oral telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telmisartan 80 mg/day (n=2903)
Study: 10590490
Drug: Beta-blockers (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (e.g., carvedilol)
Study: 10590490
Drug: EP guided
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP guided therapy
Study: 1605660
Drug: Norfloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (800 mg, orally QID)
Study: 6374774
Drug: etidocaine 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: etidocaine 1.5% with ornipressine 1 IU/10 ml (n = 10)
Study: 27503474
Drug: Typhoid polysaccharide
Normalized name: Typhoid polysaccharide vaccine in parenteral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid polysaccharide vaccine
Study: 25252510
Drug: Eutectic Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic Mixture of Local Anaesthetics cream (2g applied to injection site)
Study: 25252510
Drug: Rattle (shaken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rattle (shaken for 30s to 15s before injection)
Study: 25252510
Drug: Eutectic Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic Mixture of Local Anaesthetics cream
Study: 20876734
Drug: NT-proBNP guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP guided therapy
Study: 20876734
Drug: Guideline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatment
Study: 10027027
Drug: Dixyrazine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixyrazine 0.25 mg kg‐1
Study: 7015021
Drug: Minidose propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minidose propranolol (5 to 10 mg/6 hr)
Study: 7015021
Drug: Propranolol postoperatively
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol postoperatively (not specified dosage)
Study: 26378246
Drug: Caffeine (dose-dependent)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (dose-dependent)
Study: 22879443
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and spine strengthening exercises
Study: 17130429
Drug: Carbamazepine as
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine as monotherapy
Study: 17130429
Drug: Valproate as
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate as monotherapy
Study: 17130429
Drug: Delayed antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antiepileptic drug treatment
Study: 9292072
Drug: Solution vehicles
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution vehicles and empty chamber
Study: 3518596
Drug: Fluoxymesterone (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxymesterone (synthetic androgen) for 3 days before and on the day of chemotherapy
Study: 3518596
Drug: Cyclic chemotherapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic chemotherapy with aminoglutethimide and hydrocortisone
Study: 22520267
Drug: Dose to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to the anal surface at 53 Gy
Study: 22520267
Drug: Mean dose
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean dose to the anal surface
Study: 19669773
Drug: Intracorporeal pneumatic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracorporeal pneumatic shock therapy (IPST)
Study: 12227275
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (Verteporfin)
Study: 8550248
Drug: CoQ10 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (150 mg/day for 2 months)
Study: 2693917
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta-estradiol (Estraderm)
Study: 31880370
Drug: Kisspeptin-10 (Kp10)
Normalized name: Kisspeptin-10
DrugBank: Kisspeptin-10 (DB16210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin-10 (Kp10) injection (5 µg/kg body weight), administered intramuscularly once a week for 1 month
Study: 30935545
Drug: Propolis (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (500 mg, three times a day for 8 weeks)
Study: 29145288
Drug: Cold application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold application (600-g ice packs for 15 minutes before CTR)
Study: 29145288
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (tap water packs)
Study: 23053900
Drug: Mosapride (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (30 mg) plus esomeprazole (40 mg)
Study: 23053900
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus esomeprazole (40 mg)
Study: 18752430
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A virus (HAV) vaccine
Study: 18752430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received TT vaccine first, then HAV vaccine)
Study: 7529468
Drug: Large-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large-dose aprotinin (initial dose of 2,000,000 KIU followed by infusion of 500,000 KIU/h)
Study: 7529468
Drug: Small-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small-dose aprotinin (initial dose of 500,000 KIU followed by infusion of 150,000 KIU/h)
Study: 28712353
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention for PTSD (CBT-P), 12-16 sessions
Study: 22237990
Drug: Seating force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seating force of 10 g
Study: 22237990
Drug: Seating force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seating force of 50 g
Study: 22237990
Drug: Seating force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seating force of 100 g
Study: 22237990
Drug: Seating force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seating force of 500 g
Study: 22237990
Drug: Seating force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seating force of 750 g
Study: 21671496
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy (esomeprazole 20 mg, clarithromycin 0.5 g, amoxicillin 1.0 g, bismuth potassium citrate 220 mg for 7 days)
Study: 21671496
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (esomeprazole 20 mg, clarithromycin 0.5 g, amoxicillin 1.0 g for 7 days)
Study: 19086083
Drug: Early-start rasagiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-start rasagiline treatment
Study: 19086083
Drug: Delayed-start rasagiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-start rasagiline treatment (placebo for 6 months)
Study: 12077522
Drug: 20% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% azelaic acid formulation
Study: 12077522
Drug: Topical whitening
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical whitening agents
Study: 10465378
Drug: Transdermal gel
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal gel (1.5 mg oestradiol)
Study: 10465378
Drug: Tablet (2
Normalized name: VOYDEYA Tablet (200mg Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (2 mg oestradiol valerate)
Study: 475944
Drug: Hyoscine hydrobromide
Normalized name: Hyoscine hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine hydrobromide (0.3 mg)
Study: 25251893
Drug: Midazolam-meperidine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-meperidine combination (group-MM)
Study: 23782589
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of fish oil (approximately 3.6 g/day of LCn‐3PUFA)
Study: 23782589
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of corn oil (placebo)
Study: 19207321
Drug: Fanning injection
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fanning injection technique
Study: 17161821
Drug: FTY720 (0.25-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (0.25-2 mg)
Study: 17161821
Drug: FTY720 (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (3.5 mg)
Study: 9920537
Drug: Norgestimate and
Normalized name: norgestimate and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate and ethinyl estradiol (0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) for 3 weeks followed by 1 week of inactive tablets
Study: 9920537
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 4 weeks
Study: 2972549
Drug: Cetirizine di-HCl
Normalized name: LEVOCETIRIZINE DI-HCL 2.5MG/5ML ORAL SOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine di-HCl (10 mg)
Study: 2972549
Drug: Dexchlorpheniramine maleate
Normalized name: Dexchlorpheniramine Maleate
DrugBank: Dexchlorpheniramine (DB13679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexchlorpheniramine maleate (6 mg)
Study: 23611305
Drug: Older cousin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older cousin with drug abuse (DA)
Study: 20369616
Drug: Remaxol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol infusion solution
Study: 17578978
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg before surgery and 200 mg every 12 h for 14 days postoperatively
Study: 15589464
Drug: Fenoldopam infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam infusion at 0.025 microg/kg/min titrated to 0.1 microg/kg/min for 48 hours post-op
Study: 15589464
Drug: Antibody induction
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody induction (AI) using antithymocyte globulin (AT-G(r))
Study: 12110157
Drug: Diagnostic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic and treatment algorithms to optimize antibiotic use in nursing homes
Study: 2157313
Drug: Ibopamine 200
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 200 mg plus Furosemide 40 mg
Study: 16251617
Drug: NaFeEDTA-fortified fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA-fortified fish sauce (9 mmol (500 mg) Fe/L) for 18 months
Study: 9632998
Drug: Potent combination
Normalized name: Corticosteroids, potent, other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent combination antiretroviral therapy
Study: 9004781
Drug: Zinc Acexamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc Acexamate (600 mg/d)
Study: 31660706
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg/d)
Study: 6398312
Drug: Thymopentin administered
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin administered subcutaneously (s.c.)
Study: 6398312
Drug: Thymopentin administered
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin administered intravenously (i.v.)
Study: 29932784
Drug: Internet-based mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based mindfulness-based cognitive therapy (eMBCT)
Study: 24994476
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (n = 8)
Study: 24994476
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 11)
Study: 14515443
Drug: ALL-BFM 90
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALL-BFM 90 protocol chemotherapy for 2 years
Study: 8879341
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg)
Study: 8879341
Drug: Bisoprolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (2.5 to 10 mg)/Hydrochlorothiazide (HCTZ) 6.25
Study: 8879341
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 20 mg)
Study: 31245907
Drug: Iguratimod plus
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod plus corticosteroid (diprospan, intramuscular injection, 25 mg, twice daily for 24 weeks)
Study: 22409849
Drug: Cryoablation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoablation treatment
Study: 17699388
Drug: Low-dosage enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage enoxaparin
Study: 8072077
Drug: Oral methyltestosterone
Normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methyltestosterone (2 different commercial preparations) for 1 month
Study: 31402742
Drug: Inverse prism
Normalized name: Inversedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse prism (IP) therapy
Study: 31402742
Drug: Conventional prism
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional prism (CP) therapy
Study: 21355718
Drug: Intradermal microneedle
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal microneedle delivery of insulin lispro (IL)
Study: 18536954
Drug: Cinacalcet (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (15 then 30 mg/day)
Study: 16890577
Drug: Lopinavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily)
Study: 16890577
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg twice daily (after dose adjustment)
Study: 16890577
Drug: Lamotrigine 50
Normalized name: lamotrigine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 50 mg once daily on days 1 and 2 and 100 mg twice daily on day 3 through day 10
Study: 11359886
Drug: Amorphous hydrogel
Normalized name: HYDROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorphous hydrogel dressing (Intrasite Gel)
Study: 8267175
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 ng/mL
Study: 8267175
Drug: Alfentanil 28.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 28.8 ng/mL
Study: 3311051
Drug: Triamcinolone subacromial
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone subacromial bursa injection
Study: 3311051
Drug: Naproxen therapy
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen therapy
Study: 30842172
Drug: Single-dose RSB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose RSB analgesia
Study: 27398889
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine for 72 hours
Study: 25736126
Drug: DEX 0.3
Normalized name: Ciprodex 0.3%-0.1% Otic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0.3 micro;g/kg followed by propofol 1 mg/kg (group D)
Study: 25736126
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg (group C)
Study: 19906340
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (2-15 mg/d)
Study: 19906340
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (in risperidone subgroup)
Study: 19906340
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (in quetiapine subgroup)
Study: 17692117
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (0.05 units/kg/h)
Study: 12487852
Drug: (186)Re-lipiodol (RL)
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: (186)Re-lipiodol (RL) administered at doses ranging from 1 110 MBq to 2 220 MBq per patient depending on tumor volume.
Study: 7636556
Drug: Single 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20-mg IV dose of dexamethasone plus single 32-mg IV dose of ondansetron
Study: 7636556
Drug: Single 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20-mg IV dose of dexamethasone plus single 24-mg IV dose of ondansetron
Study: 7636556
Drug: Single 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20-mg IV dose of dexamethasone plus single 8-mg IV dose of ondansetron
Study: 2236435
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/Kg b.i.d.)
Study: 27093
Drug: Rolaids (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolaids (2 tablets)
Study: 27093
Drug: Di-Gel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-Gel (2 tablets)
Study: 27093
Drug: Maalox liquid
Normalized name: Maalox Max Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox liquid (15 ml)
Study: 27093
Drug: Conquel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conquel (2 tablets)
Study: 27784414
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Insomnia Therapy (CBT-I)
Study: 27784414
Drug: Quasi-desensitization Control
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quasi-desensitization Control (CTRL) therapy
Study: 27784414
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (escitalopram, sertraline, desvenlafaxine) with either CBT-I or CTRL
Study: 9307129
Drug: Prior administration
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior administration of dextromethorphan (a N‐methyl‐D‐aspartate receptor antagonist).
Study: 8458045
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol (0.25, 0.5, 1, or 2 mg)
Study: 28010731
Drug: Heavy clinical
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy clinical workload, shift patterns of work, inadequate number of trained staff, time and setting of consent seeking, non-availability of research staff out of hours, parents' concerns about experimental medicine
Study: 21660402
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (2 mg/kg/d, maximum 20 mg in 2 divided doses, for 5 days)
Study: 18434918
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system worn for 4 hours
Study: 18434918
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system worn for 6 hours
Study: 18434918
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (various doses: 10, 15, 20, or 30 mg) worn for 9 hours
Study: 16544177
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg deoxyspergualin (DSG)
Study: 16544177
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg deoxyspergualin (DSG)
Study: 16544177
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of deoxyspergualin (DSG)
Study: 10718390
Drug: Synergistic sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergistic sedation with low-dose midazolam and propofol (group II), median dose of 2 mg midazolam and median 100 mg propofol (IQR 53 to 145) with a maximal bolus of 50 mg.
Study: 10718390
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination of midazolam and nalbuphine (group I), median dose of 9 mg midazolam (IQR 6 to 12) and median 20 mg nalbuphine (IQR 10 to 20).
Study: 1350366
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 micrograms morning and evening)
Study: 1350366
Drug: Theophylline-ketotifen association
Normalized name: ketotifen / theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline-ketotifen association (300 mg and 1 mg morning and evening)
Study: 27525532
Drug: SC administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC administration of 20 mcg of teriparatide every 12 hours until discharge
Study: 22154591
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy plus adjuvant chemotherapy
Study: 16263827
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg melatonin